Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphosys AG (GB:0NDV)
LSE:0NDV
Morphosys (0NDV) Share Price & Analysis
1 Followers
0NDV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€14.56 - €69.65
Previous Close€67.8
Volume1.18K
Average Volume (3M)43.82K
Market Cap
€2.55B
Enterprise Value€2.65B
Total Cash (Recent Filing)€158.50M
Total Debt (Recent Filing)€256.45M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 29, 2024EPS Estimate
-€2.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.75
Shares Outstanding37,655,137
10 Day Avg. Volume16,390
30 Day Avg. Volume43,818
Standard Deviation0.11
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.73
Price to Sales (P/S)15.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€68.00Price Target Upside0.29% Upside
Rating ConsensusHold
Number of Analyst Covering3
Morphosys News
Bulls Say, Bears Say
Bulls Say
AcquisitionThe company confirms the acquisition deal with NVS is on track to close.
RegulatoryThe NDA filing for pelabresib is expected.
ValuationAnalysts reiterate a €68 price target based on the NVS acquisition.
Bears Say
Clinical CautionClinicians would likely remain cautious about adding pelabrasib to Jakafi until the true long-term safety of the regimen has been established.
Regulatory ConcernsA warning letter was issued by the FDA to physicians involved in the MANIFEST-2 trial.
Safety IssuesPhysicians involved in the trial disclosed multiple cases of AML transformation in the Phase 3 MANIFEST-2.
---
0NDV FAQ
What was Morphosys AG’s price range in the past 12 months?
Morphosys AG lowest share price was €14.55 and its highest was €69.65 in the past 12 months.
What is Morphosys AG’s market cap?
Currently, no data Available
When is Morphosys AG’s upcoming earnings report date?
Morphosys AG’s upcoming earnings report date is Aug 29, 2024 which is in 37 days.
How were Morphosys AG’s earnings last quarter?
Morphosys AG released its earnings results on Apr 29, 2024. The company reported -€8.27 earnings per share for the quarter, missing the consensus estimate of -€1.129 by -€7.141.
Is Morphosys AG overvalued?
According to Wall Street analysts Morphosys AG’s price is currently Undervalued.
Does Morphosys AG pay dividends?
Morphosys AG does not currently pay dividends.
What is Morphosys AG’s EPS estimate?
Morphosys AG’s EPS estimate is -€2.58.
How many shares outstanding does Morphosys AG have?
Morphosys AG has 37,716,423 shares outstanding.
What happened to Morphosys AG’s price movement after its last earnings report?
Morphosys AG reported an EPS of -€8.27 in its last earnings report, missing expectations of -€1.129. Following the earnings report the stock price went up 1.223%.
Which hedge fund is a major shareholder of Morphosys AG?
Currently, no hedge funds are holding shares in GB:0NDV
---
Morphosys Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.85%
Trailing 12-Months
Company Description
Morphosys AG
MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.
---
0NDV Stock 12 Month Forecast
Average Price Target
€68.00
▲(0.29% Upside)
Technical Analysis
Best Analysts Covering 0NDV
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+13.92%
reiterated a buy rating 6 months ago
Copying James Gordon's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +13.92% per trade.
---